Lung Disease

Targeting mechanosensitive protein could treat pulmonary fibrosis, study suggests

Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the Journal of Experimental Medicine (JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.

Immune cell implicated in development of lung disease following viral infection

Scientists at Washington University School of Medicine in St. Louis have implicated a type of immune cell in the development of chronic lung disease that sometimes is triggered following a respiratory viral infection. The evidence suggests that activation of this immune cell serves as an early switch that, when activated, drives progressive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).

Researchers Identify “Druggable” Signaling Pathway that Stimulates Lung Tissue Repair

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have identified a cellular pathway that can be targeted with a naturally occurring drug to stimulate lung tissue regeneration, which is necessary for recovery from multiple lung injuries. The findings, which were published today in Nature Cell Biology, could lead to better therapies for patients with lung disease, including acute respiratory distress syndrome (ARDS) due to COVID-19.

Press Register Now; ATS 2020 Virtual Starts Aug. 5

Join us on Aug. 5-10 2020 for ATS 2020 Virtual, when the American Thoracic Society will host a mix of live and pre-recorded sessions in pulmonary, critical care, and sleep medicine. Press are invited to attend (see press guidelines) and may register now. Same day registration will be available during the meeting.

ECMO Physicians Offer Guidance in the Context of Resource-scarce COVID-19 Treatment

Rapidly escalating numbers of COVID-19 patients suffering from respiratory failure threaten to overwhelm hospital capacity and force healthcare providers into making challenging decisions about the care they provide. Of particular interest is the role of ECMO – extracorporeal membrane oxygenation, a form of life support for patients with advanced lung disease – to support critically ill patients in the current pandemic.

Maternal Antibiotic Treatment May Harm Preemies’ Lungs

New research in mice suggests that exposure to antibiotics before birth may impair lung development in premature infants. The study, the first to explore the gut-lung axis in prematurity, is published ahead of print in the American Journal of Physiology—Lung Cellular and Molecular Physiology and was chosen as an APSselect article for December.